Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Terminated 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 72Breast Neoplasms 9Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Prostate Cancer Metastatic 3Metastatic Castration Resistant Prostate Cancer 3Bulbo-Spinal Atrophy, X-Linked 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Metastatic Hormone Sensitive Prostate Cancer 2Melanoma 2mCRPC 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Solid Tumours 1Small Cell Lung Carcinoma 1Seizures 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Pancreatic Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Squamous Cell 1Metastatic Progressive Castration-resistant Prostate Cancer 1

Interventions

enzalutamide 5olaparib 4Abiraterone Acetate 4radium Ra 223 dichloride 2poly ICLC 1fluciclovine F-18 1darolutamide 1bempegaldesleukin 1avelumab 1abiraterone 1Radiosurgery 1Prednisone 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Metastatic Castration-resistant Prostate Cancer × enzalutamide × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Tulane University

Phase 2 Terminated
8 enrolled 7 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

AstraZeneca

Phase 3 Completed
387 enrolled 16 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT01942837 2022-10-24

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
67 enrolled 17 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04237584 2022-10-07

ESCALATE

MANA RBM

Phase 3 Terminated
23 enrolled 11 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡